US2016367493A1PendingUtilityA1

Method and improved pharmaceutical composition for enhancing transdermal delivery of pde-5 inhibitor

26
Assignee: TRITECH BIOPHARMACEUTICALS CO LTDPriority: Dec 26, 2011Filed: Jun 16, 2016Published: Dec 22, 2016
Est. expiryDec 26, 2031(~5.4 yrs left)· nominal 20-yr term from priority
Inventors:Yee-Chien LiuPei-Ling Wu
A61P 9/00A61P 43/00A61P 15/00A61P 11/00A61P 15/10A61K 47/16A61K 47/10A61K 9/0014A61K 9/7023A61K 31/4985A61K 47/08A61K 47/22A61K 31/53A61K 9/06A61K 31/519A61K 47/186
26
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to the use of an agent that enhances transdermal delivery of a PDE-5 inhibitor. More particularly, the present disclosure provides improved method and composition that promotes transdermal delivery of a PDE-5 inhibitor for the treatment of the PDE-5 mediated conditions and/or diseases.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A transdermal pharmaceutical gel or patch composition comprising:
 an effective amount of vardenafil or a pharmaceutically acceptable salt thereof and an enhancer for enhancing transdermal delivery of vardenafil; wherein the enhance is cocamidopropyl betaine, and vardenafil and the enhancer are present in a ratio from about 20:1 to 2:1 by weight in the transdermal pharmaceutical gel or patch composition; and   a pharmaceutically acceptable excipient.   
     
     
         2 . The transdermal pharmaceutical gel or patch composition of  claim 1 , wherein vardenafil and the enhancer are present in the transdermal pharmaceutical gel or patch composition in a ratio of about 17:1. 
     
     
         3 . The transdermal pharmaceutical gel or patch composition of  claim 1 , wherein vardenafil and the enhancer are present in the transdermal pharmaceutical gel or patch composition in a ratio of about 10:1. 
     
     
         4 . The transdermal pharmaceutical gel or patch composition of  claim 1 , wherein vardenafil and the enhancer are present in the transdermal pharmaceutical gel or patch composition in a ratio of about 3:1. 
     
     
         5 . The transdermal pharmaceutical gel or patch composition of  claim 1 , wherein vardenafil is not in a crystalline state. 
     
     
         6 . A method for enhancing transdermal delivery of vardenafil in a subject comprising administering to the subject an effective amount of the transdermal pharmaceutical gel or patch composition of  claim 1 . 
     
     
         7 . The method of  claim 6 , wherein vardenafil and the enhancer are present in the transdermal pharmaceutical gel or patch composition in a ratio of about 17:1 by weight. 
     
     
         8 . The method of  claim 6 , wherein vardenafil and the enhancer are present in the transdermal pharmaceutical gel or patch composition in a ratio of about 10:1 by weight. 
     
     
         9 . The method of  claim 6 , wherein vardenafil and the enhancer are present in the transdermal pharmaceutical gel or patch composition in a ratio of about 3:1 by weight. 
     
     
         10 . The method of  claim 6 , wherein vardenafil is not in a crystalline state.

Join the waitlist — get patent alerts

Track US2016367493A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.